Therapeutic Intensification Based on Immune Checkpoint Inhibitors in . . . Given that systemic immunotherapy is becoming an increasingly important treatment option for NMIBC, we aimed to provide a comprehensive review of the key evidence and future perspectives on therapeutic intensification strategies involving immune checkpoint inhibitors in both BCG-unresponsive and BCG-naïve high-risk NMIBC
First-line treatments for BCG-naïve non-muscle invasive . . . - Springer This systematic review and meta-analysis of RCTs aims to assess the statistical, clinical, and oncologic efficacy, as well as the tolerability, of adding therapies to intravesical BCG or replacing BCG in BCG-naïve HRNMIBC patients following transurethral resection of bladder tumor (TURBT)
Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive . . . This review focuses on the evaluation of current evidence and ongoing clinical trials to assess the efficacy and safety of immune checkpoint inhibitors (ICIs), both as monotherapies and in combination regimens, for managing BCG-unresponsive NMIBC (Table 2)
Ongoing clinical trials of BCG ICI combinations in BCG-naïve NMIBC Take a look through the key trials investigating BCG ICI combinations in BCG-naïve NMIBC In BCG-naïve non–muscle invasive bladder cancer (NMIBC), emerging options are largely focused on combining BCG with immune checkpoint inhibitors (ICIs)
Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder . . . Bacillus Calmette-Guérin (BCG) is the standard treatment for patients with non-muscle invasive bladder cancer (NMIBC) Although this therapy has been effective, BCG resistance poses a significant challenge, highlighting the need for alternative treatment options
Immunotherapy Escalation in BCG-Naïve NMIBC: Time for Selectivity, Not . . . The recent wave of phase 3 trials evaluating checkpoint inhibitors in bacillus Calmette–Guérin (BCG)-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) (ALBAN [1], CREST [2], and POTOMAC [3,4]) marks a defining moment for bladder cancer therapies